To investigate the clinical impact of ESR1 mutations in cfDNA on the efficacy of chemotherapy in metastatic ER+/HER2- breast cancer patients, we analyzed plasma samples from advanced ER+ breast cancer patients that were treated with first-line paclitaxel/bevacizumab in the ATX trial. This evidence concerns the gene ERBB2 and breast carcinoma.